AddedMD&A
investment gains or losses and proceeds from the recovery of a note receivable, compared to the same period in the prior year.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
AddedMD&A
On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. Where relevant, the Company has reflected any material items that were enacted in the consolidated financial statements for the year ended December 31, 2025.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
AddedMD&A
with the expected holding period of the stock options. We have assumed a dividend yield of zero as we have not historically paid any dividends on our common stock.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RemovedMD&A
companies based on our ability to consistently utilize our full-service, disciplined operating model to deliver timely and high-quality results for our customers.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
As of February 6, 2025, the Company's Board of Directors approved an increase of $600.0 million to the Company's new stock repurchase program.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
On September 30, 2019 (the “Closing Date”), the Company obtained an unsecured credit facility (as amended from time to time, the “Credit Facility”) through its wholly owned subsidiaries, Medpace, Inc., as borrower (the “Borrower”), and Medpace IntermediateCo, Inc., as guarantor (the “Guarantor”).
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On March 31, 2023, the Company entered into Amendment No. 5 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit to up to $150.0 million, adjusted the interest rate and fee charged on the credit facility and extended the expiration date of resolving credit note to March 29, 2024. On March 28, 2024, the Company entered into Amendment No. 6 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit to up to $10.0 million, and extended the expiration date of revolving credit note to March 31, 2025.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
The Credit Facility is guaranteed by the Guarantor and its material, direct or indirect wholly owned domestic subsidiaries, with certain exceptions, including where providing such guarantees is not permitted by law, regulation or contract or would result in adverse tax consequences. All of the obligations under the Credit Facility are unsecured.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
The Credit Facility is subject to customary negative covenants. The Company was in compliance with all financial covenants as of December 31, 2024.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
The Credit Facility contains certain events of default, including, among others, non-payment of principal or interest, breach of the covenants, cross default and cross acceleration to certain other indebtedness, defaults on monetary judgment orders, certain ERISA events, certain bankruptcy and insolvency events, actual or asserted invalidity of any guarantee or security document and change in control.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RewordedMD&A
Changes in operating assets and liabilities provided $157.2 $96.3 million in operating cash flows and were was primarily driven by increased advanced billings of $150.7 $143.8 million, increased accrued expenses of $97.1 million and changes in Other assets and liabilities, net of $23.8 million, and increased accrued expenses of $16.9 $11.2 million, partially offset by decreased lease liabilities increased accounts receivable and unbilled, net of $21.4 million and $106.2 million, increased prepaid expenses and other current assets of $12.1 $27.1 million and decreased lease liabilities of $25.2 million.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
The This change was mainly attributable to foreign exchange gains or losses that arise in connection with the revaluation of short-term inter-company intercompany balances between our domestic and international subsidiaries, gains or losses from foreign currency transactions, such as those resulting subsidiaries and from the settlement of third-party accounts receivables and payables denominated in a currency other than the local currency of the entity making the payment and proceeds from the recovery of a note receivable, compared to the same period in the prior year. payment, third-party
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in the income tax provision was primarily attributable to the increase in pre-tax book income, increase in uncertain tax positions, increase in Global Intangible Low-Taxed Income ("GILTI") (net of foreign tax credits), and decrease in tax benefits related to Foreign Derived Intangible Income ("FDII") which was partially offset by an increase in excess tax benefits recognized from share-based compensation and a decrease in uncertain tax positions, compensation, compared to the same period in the prior year.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in the income overall effective tax provision rate was primarily attributable to the a decrease in tax benefits related to FDII, increase in pre-tax book income, uncertain tax positions and an increase in GILTI (net of foreign tax credits) which was partially offset by an increase in excess tax benefits recognized from share-based compensation and a decrease in uncertain tax positions, compared to the same period in the prior year.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
Miscellaneous income (expense), (expense) income, net changed by $4.7 million, $9.4 million of expense, to $5.3 million of expense for the year ended December 31, 2025, from $4.1 million of income for the year ended December 31, 2024 from $0.7 million of expense for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
The effect of foreign currency adjustments on backlog was as follows: favorable foreign currency adjustments of $25.1 million for the year ended December 31, 2025 and unfavorable foreign currency adjustments of $16.7 million for the year ended December 31, 2024 and favorable foreign currency adjustments of $14.6 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
Adjustments to reconcile net income to net cash provided by operating activities were $47.2 $165.8 million, primarily related to depreciation deferred income tax provision of $27.8 $80.8 million, stock-based compensation expense of $25.5 $34.8 million, depreciation of $27.2 million and noncash lease expense of $23.1 million, partially offset by a deferred income tax benefit of $26.6 $23.0 million.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
Total revenue increased by $223.2 $421.2 million, to $2,530.2 million to for the year ended December 31, 2025, from $2,109.1 million for the year ended December 31, 2024, from $1,885.8 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
Income tax provision increased by $18.7 $19.7 million, to $91.3 million for the year ended December 31, 2025, from $71.5 million for the year ended December 31, 2024 from $52.9 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
We believe that we are a partner of choice for small- and mid-sized biopharmaceutical companies based on our ability to consistently utilize our full-service, disciplined operating model to deliver timely and high-quality results for our customers.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
The Organization for Economic Co-operation and Development (OECD) ("OECD") has a framework to implement a global minimum corporate tax of 15% for companies with global revenues and profits above certain thresholds (referred to as Pillar Two), with certain aspects of Pillar Two effective January 1, 2024 and other aspects effective January 1, 2025. Two).
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
The assumptions used in the table above reflect both grant date inputs to arrive at the grant date fair values for stock options subject to equity-classified stock compensation accounting and reflect a fair value calculation for stock options outstanding in the period subject to liability-classified stock compensation accounting.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new